Bibliographic Details
| Title: |
Barriers and opportunities in pancreatic cancer immunotherapy |
| Authors: |
Yixin Ju, Dongzhi Xu, Miao-miao Liao, Yutong Sun, Wen-dai Bao, Fan Yao, Li Ma |
| Source: |
npj Precision Oncology, Vol 8, Iss 1, Pp 1-18 (2024) |
| Publisher Information: |
Nature Portfolio, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Abstract Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and limited therapeutic efficacy. Immunotherapy, a proven success in multiple cancers, has yet to demonstrate significant benefits in PDAC. Recent studies have revealed the immunosuppressive characteristics of the PDAC tumor microenvironment (TME), including immune cells with suppressive properties, desmoplastic stroma, microbiome influences, and PDAC-specific signaling pathways. In this article, we review recent advances in understanding the immunosuppressive TME of PDAC, TME differences among various mouse models of pancreatic cancer, and the mechanisms underlying resistance to immunotherapeutic interventions. Furthermore, we discuss the potential of targeting cancer cell-intrinsic pathways and TME components to sensitize PDAC to immune therapies, providing insights into strategies and future perspectives to break through the barriers in improving pancreatic cancer treatment. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2397-768X |
| Relation: |
https://doaj.org/toc/2397-768X |
| DOI: |
10.1038/s41698-024-00681-z |
| Access URL: |
https://doaj.org/article/b6243d17a34b4d15be4fbc178195cb6a |
| Accession Number: |
edsdoj.b6243d17a34b4d15be4fbc178195cb6a |
| Database: |
Directory of Open Access Journals |
